GlassScriptPhysician profile
Daniel R Alvarez
NPI 1588646236
$16,445.29
in general payments reported to CMS, 2019-2025
47 companies · $2,187 in 2025
The $2,187 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $2,392 · 2021: $3,909 · 2022: $2,426 · 2023: $1,935 · 2024: $1,686 · 2025: $2,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,714 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,713.83 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,436.84 | 2020-2025 | Jot Dx, Assurity, Gallant |
| Janssen Pharmaceuticals, INC | $1,468.79 | 2019-2024 | Xarelto |
| Amgen INC. | $1,285.54 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,110.87 | 2019-2025 | Wainua, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $1,088.40 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $909.39 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $773.79 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $759.74 | 2019-2020 | |
| Amarin Pharma, INC. | $665.43 | 2019-2022 | |
| Pfizer INC. | $543.14 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $496.33 | 2021-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $441.47 | 2021-2025 | |
| Medtronic, INC. | $393.74 | 2021-2022 | |
| Esperion Therapeutics, INC. | $308.94 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $298.32 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.